These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18813797)

  • 1. Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2.
    Janke M; Peeters B; Zhao H; de Leeuw O; Moorman R; Arnold A; Ziouta Y; Fournier P; Schirrmacher V
    Int J Oncol; 2008 Oct; 33(4):823-32. PubMed ID: 18813797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy.
    Janke M; Peeters B; de Leeuw O; Moorman R; Arnold A; Fournier P; Schirrmacher V
    Gene Ther; 2007 Dec; 14(23):1639-49. PubMed ID: 17914407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
    Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
    Mol Ther; 2006 Jan; 13(1):183-93. PubMed ID: 16125469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity.
    Fournier P; Aigner M; Schirrmacher V
    Int J Oncol; 2011 Jun; 38(6):1719-29. PubMed ID: 21424118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
    Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
    Vaccine; 2005 Mar; 23(19):2439-53. PubMed ID: 15752830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules.
    Haas C; Herold-Mende C; Gerhards R; Schirrmacher V
    Cancer Gene Ther; 1999; 6(3):254-62. PubMed ID: 10359211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus.
    Schirrmacher V; Haas C; Bonifer R; Ahlert T; Gerhards R; Ertel C
    Gene Ther; 1999 Jan; 6(1):63-73. PubMed ID: 10341877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus.
    Bian H; Fournier P; Moormann R; Peeters B; Schirrmacher V
    Cancer Gene Ther; 2005 Mar; 12(3):295-303. PubMed ID: 15605075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy.
    Zhao H; Janke M; Fournier P; Schirrmacher V
    Virus Res; 2008 Sep; 136(1-2):75-80. PubMed ID: 18538434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
    Haas C; Strauss G; Moldenhauer G; Iorio RM; Schirrmacher V
    Clin Cancer Res; 1998 Mar; 4(3):721-30. PubMed ID: 9533542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma.
    Ockert D; Schirrmacher V; Beck N; Stoelben E; Ahlert T; Flechtenmacher J; Hagmüller E; Buchcik R; Nagel M; Saeger HD
    Clin Cancer Res; 1996 Jan; 2(1):21-8. PubMed ID: 9816085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous tumor vaccine modified with recombinant new castle disease virus expressing IL-7 promotes antitumor immune response.
    Zhao L; Mei Y; Sun Q; Guo L; Wu Y; Yu X; Hu B; Liu X; Liu H
    J Immunol; 2014 Jul; 193(2):735-45. PubMed ID: 24943214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with virus-modified tumor cells.
    Schirrmacher V; Ahlert T; Pröbstle T; Steiner HH; Herold-Mende C; Gerhards R; Hagmüller E; Steiner HH
    Semin Oncol; 1998 Dec; 25(6):677-96. PubMed ID: 9865682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
    van Herpen CM; van der Laak JA; de Vries IJ; van Krieken JH; de Wilde PC; Balvers MG; Adema GJ; De Mulder PH
    Clin Cancer Res; 2005 Mar; 11(5):1899-909. PubMed ID: 15756016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins.
    Aigner M; Janke M; Lulei M; Beckhove P; Fournier P; Schirrmacher V
    Int J Oncol; 2008 Apr; 32(4):777-89. PubMed ID: 18360705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine.
    Herold-Mende C; Karcher J; Dyckhoff G; Schirrmacher V
    Adv Otorhinolaryngol; 2005; 62():173-83. PubMed ID: 15608427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein.
    Bian H; Fournier P; Moormann R; Peeters B; Schirrmacher V
    Int J Oncol; 2005 Feb; 26(2):431-9. PubMed ID: 15645128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer.
    Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M
    Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neem leaf glycoprotein induces perforin-mediated tumor cell killing by T and NK cells through differential regulation of IFNgamma signaling.
    Bose A; Chakraborty K; Sarkar K; Goswami S; Chakraborty T; Pal S; Baral R
    J Immunother; 2009 Jan; 32(1):42-53. PubMed ID: 19307993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells.
    Karcher J; Dyckhoff G; Beckhove P; Reisser C; Brysch M; Ziouta Y; Helmke BH; Weidauer H; Schirrmacher V; Herold-Mende C
    Cancer Res; 2004 Nov; 64(21):8057-61. PubMed ID: 15520216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.